Lenvatinib acts on platelet‑derived growth factor receptor &beta; to suppress the malignant behaviors of gastric cancer cells

Tong,Xiaoyi; Du,Jun; Jiang,Qiaoling; Wu,Qiaoli; Zhao,Shuxia; Chen,Shuhang

doi:10.3892/ol.2024.14616

Lenvatinib acts on platelet‑derived growth factor receptor β to suppress the malignant behaviors of gastric cancer cells

Authors:
- Xiaoyi Tong
- Jun Du
- Qiaoling Jiang
- Qiaoli Wu
- Shuxia Zhao
- Shuhang Chen
View Affiliations

Affiliations: Graduate School, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310000, P.R. China, Department of Nursing, Lanxi People's Hospital, Jinhua, Zhejiang 321100, P.R. China, Department of Clinical Laboratory, Lanxi People's Hospital, Jinhua, Zhejiang 321100, P.R. China, Department of Pharmacy, Lanxi People's Hospital, Jinhua, Zhejiang 321100, P.R. China, Department of Gastroenterology, Lanxi People's Hospital, Jinhua, Zhejiang 321100, P.R. China
Published online on: August 7, 2024 https://doi.org/10.3892/ol.2024.14616
Article Number: 483
Copyright: © Tong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Given the limited treatment options and high mortality rates associated with gastric cancer, there is a need to explore novel therapeutic options. The present study aimed to investigate the efficacy of lenvatinib, a multi‑target tyrosine kinase inhibitor, in mitigating the progress of gastric cancer in vitro. Comprehensive analyses were conducted to assess the impact of lenvatinib on gastric cancer cells, focusing on the inhibition of viability, suppression of proliferation, induction of apoptosis and reduction of metastatic potential. The effects of lenvatinib on these activities were determined using 5‑ethynyl‑2'‑deoxyuridine staining, colony formation assay, flow cytometry, western blotting, scratch assay and Transwell assay. In addition, bioinformatics analyses were employed to identify key regulatory targets of lenvatinib, with particular attention given to platelet‑derived growth factor receptor β (PDGFRB). In addition, the effects of PDGFRB overexpression on the regulation of lenvatinib were explored. Lenvatinib demonstrated significant inhibitory effects on the viability, proliferation and metastatic capabilities of MKN45 and HGC27 gastric cancer cell lines. Bioinformatics analyses identified PDGFRB as a crucial target of lenvatinib, with its downregulation showing promise in enhancing overall survival rates of patients with gastric cancer. By contrast, PDGFRB overexpression reversed the effects of lenvatinib on cells. The present findings underscore the potential of lenvatinib as a promising therapeutic option in the treatment of gastric cancer. By elucidating its mechanism of action and identifying PDGFRB as a primary target, the present study may aid further clinical advancements.

View Figures

View References

1	Machlowska J, Baj J, Sitarz M, Maciejewski R and Sitarz R: Gastric cancer: Epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 21:40122020. View Article : Google Scholar : PubMed/NCBI
2	Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI
3	Yang K, Lu L, Liu H, Wang X, Gao Y, Yang L, Li Y, Su M, Jin M and Khan S: A comprehensive update on early gastric cancer: Defining terms, etiology, and alarming risk factors. Expert Rev Gastroenterol Hepatol. 15:255–273. 2021. View Article : Google Scholar : PubMed/NCBI
4	Conti CB, Agnesi S, Scaravaglio M, Masseria P, Dinelli ME, Oldani M and Uggeri F: Early gastric cancer: Update on prevention, diagnosis and treatment. Int J Environ Res Public Health. 20:21492023. View Article : Google Scholar : PubMed/NCBI
5	Xia JY and Aadam AA: Advances in screening and detection of gastric cancer. J Surg Oncol. 125:1104–1109. 2022. View Article : Google Scholar : PubMed/NCBI
6	Repetto O, Vettori R, Steffan A, Cannizzaro R and De Re V: Circulating proteins as diagnostic markers in gastric cancer. Int J Mol Sci. 24:169312023. View Article : Google Scholar : PubMed/NCBI
7	Farran B, Müller S and Montenegro RC: Gastric cancer management: Kinases as a target therapy. Clin Exp Pharmacol Physiol. 44:613–622. 2017. View Article : Google Scholar : PubMed/NCBI
8	Röcken C: Predictive biomarkers in gastric cancer. J Cancer Res Clin Oncol. 149:467–481. 2023. View Article : Google Scholar : PubMed/NCBI
9	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al: Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
10	Zeng Y and Jin RU: Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Semin Cancer Biol. 86:566–582. 2022. View Article : Google Scholar : PubMed/NCBI
11	Li AY, McCusker MG, Russo A, Scilla KA, Gittens A, Arensmeyer K, Mehra R, Adamo V and Rolfo C: RET fusions in solid tumors. Cancer Treat Rev. 81:1019112019. View Article : Google Scholar : PubMed/NCBI
12	Albarrán V, Villamayor ML, Chamorro J, Rosero DI, Pozas J, San Román M, Calvo JC, Pérez de Aguado P, Moreno J, Guerrero P, et al: Receptor tyrosine kinase inhibitors for the treatment of recurrent and unresectable bone sarcomas. Int J Mol Sci. 23:137842022. View Article : Google Scholar : PubMed/NCBI
13	Fleuren EDG, Vlenterie M and van der Graaf WTA: Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and ewing sarcoma. Front Oncol. 13:10133592023. View Article : Google Scholar : PubMed/NCBI
14	Chakraborty E and Sarkar D: Emerging therapies for hepatocellular carcinoma (HCC). Cancers (Basel). 14:27982022. View Article : Google Scholar : PubMed/NCBI
15	Liu YC, Hsu FT, Chung JG, Weng MC, Ting CY, Tsai CJ, Lan A, Wu JY, Lin CC and Lin SS: Lenvatinib induces AKT/NF-κB inactivation, apoptosis signal transduction and growth inhibition of non-small cell lung cancer in vivo. Anticancer Res. 41:2867–2874. 2021. View Article : Google Scholar : PubMed/NCBI
16	Fallahi P, Ferrari SM, Galdiero MR, Varricchi G, Elia G, Ragusa F, Paparo SR, Benvenga S and Antonelli A: Molecular targets of tyrosine kinase inhibitors in thyroid cancer. Semin Cancer Biol. 79:180–196. 2022. View Article : Google Scholar : PubMed/NCBI
17	Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, et al: Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): An open-label, single-arm, phase 2 trial. Lancet Oncol. 21:1057–1065. 2020. View Article : Google Scholar : PubMed/NCBI
18	Fei HJ, Chen SC, Zhang JY, Li SY, Zhang LL, Chen YY, Chang CX and Xu CM: Identification of significant biomarkers and pathways associated with gastric carcinogenesis by whole genome-wide expression profiling analysis. Int J Oncol. 52:955–966. 2018.PubMed/NCBI
19	Liu H, Qu Y, Zhou H, Zheng Z, Zhao J and Zhang J: Bioinformatic analysis of potential hub genes in gastric adenocarcinoma. Sci Prog. 104:3685042110042602021. View Article : Google Scholar : PubMed/NCBI
20	Karalis JD, Yoon LY, Hammer STG, Hong C, Zhu M, Nassour I, Ju MR, Xiao S, Castro-Dubon EC, Agrawal D, et al: Lenvatinib inhibits the growth of gastric cancer patient-derived xenografts generated from a heterogeneous population. J Transl Med. 20:1162022. View Article : Google Scholar : PubMed/NCBI
21	Sexton RE, Al Hallak MN, Diab M and Azmi AS: Gastric cancer: A comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 39:1179–1203. 2020. View Article : Google Scholar : PubMed/NCBI
22	Li K, Zhang A, Li X, Zhang H and Zhao L: Advances in clinical immunotherapy for gastric cancer. Biochim Biophys Acta Rev Cancer. 1876:1886152021. View Article : Google Scholar : PubMed/NCBI
23	Guan WL, He Y and Xu RH: Gastric cancer treatment: Recent progress and future perspectives. J Hematol Oncol. 16:572023. View Article : Google Scholar : PubMed/NCBI
24	Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, Pu J and Lv J: Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 29:2452–2468. 2023. View Article : Google Scholar : PubMed/NCBI
25	Patel TH and Cecchini M: Targeted therapies in advanced gastric cancer. Curr Treat Options Oncol. 21:702020. View Article : Google Scholar : PubMed/NCBI
26	Blay JY, Kang YK, Nishida T and von Mehren M: Gastrointestinal stromal tumours. Nat Rev Dis Primers. 7:222021. View Article : Google Scholar : PubMed/NCBI
27	Zhao Y, Zhang YN, Wang KT and Chen L: Lenvatinib for hepatocellular carcinoma: From preclinical mechanisms to anti-cancer therapy. Biochim Biophys Acta Rev Cancer. 1874:1883912020. View Article : Google Scholar : PubMed/NCBI
28	Lee SH, Contreras Panta EW, Gibbs D, Won Y, Min J, Zhang C, Roland JT, Hong SH, Sohn Y, Krystofiak E, et al: Apposition of fibroblasts with metaplastic gastric cells promotes dysplastic transition. Gastroenterology. 165:374–390. 2023. View Article : Google Scholar : PubMed/NCBI
29	Akiyama T, Yasuda T, Uchihara T, Yasuda-Yoshihara N, Tan BJY, Yonemura A, Semba T, Yamasaki J, Komohara Y, Ohnishi K, et al: Stromal reprogramming through dual PDGFRα/β blockade boosts the efficacy of anti-PD-1 immunotherapy in fibrotic tumors. Cancer Res. 83:753–770. 2023. View Article : Google Scholar : PubMed/NCBI
30	Liu B, Xiao X, Lin Z, Lou Y and Zhao L: PDGFRB is a potential prognostic biomarker and correlated with immune infiltrates in gastric cancer. Cancer Biomark. 34:251–264. 2022. View Article : Google Scholar : PubMed/NCBI